Feel Comfortable Sticking With NovoSeven RT Over Sevenfact

Sevenfact will join NovoSeven RT as another recombinant factor VIIa option to control bleeding in certain patients with hemophilia.

Sevenfact is currently approved to treat bleeds of any severity in patients 12 years and up with hemophilia A or B who develop "inhibitors"...antibodies to factor replacements.

Inhibitors can form against factor VIII (Advate, etc) or IX (BeneFix, etc) products...which limit their use to treat bleeding.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals